Will a cheaper diabetes pill match the original?

NCT ID NCT07763899

Completed Knowledge-focused Sponsor: ADIUM Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial asks whether a generic extended-release tablet combining sitagliptin and metformin works the same as the brand-name Janumet XR. Healthy adults aged 18 to 55 will receive a single dose of each version in random order, and researchers will compare how much of the drug reaches the bloodstream. The goal is to confirm the generic is bioequivalent, meaning it delivers the same amount of medication, which could support its approval as a lower-cost alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination tablet containing sitagliptin and metformin (50 mg/1000 mg, extended-release) compared against the brand-name version Janumet XR.
What this could lead to: If the generic tablet proves equivalent, it could offer a more affordable option for people managing type 2 diabetes.
What could go wrong: This is a small, early-stage study in healthy volunteers, not patients. Results may not predict real-world effectiveness, and the generic could still fail to match the brand drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOEQUIVALANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOEQUIVALANCE

Contacts and locations

Locations

Axis Clinicals Latina, S.A. de C.V.

Mexico City, Mexico City, 07870, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.